BusinessRitter Pharmaceuticals Announces 1-for-10 Reverse Stock SplitBy Nasdaq OMXMar 22, 2018, 3:35 PM UTC
BusinessRitter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 19, 2018, 10:35 AM UTC
BusinessRitter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock SplitBy Nasdaq OMXMar 1, 2018, 9:20 PM UTC
BusinessRitter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical TrialBy Nasdaq OMXJan 29, 2018, 2:01 PM UTC
BusinessRitter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017By Nasdaq OMXNov 29, 2017, 2:30 PM UTC
BusinessRitter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic CongressBy Nasdaq OMXNov 2, 2017, 8:51 PM UTC
BusinessRitter Pharmaceuticals, Inc. Prices $23,000,000 Public OfferingBy Nasdaq OMXSep 29, 2017, 12:00 PM UTC
BusinessRedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release CapsulesBy Nasdaq OMXAug 17, 2017, 11:00 AM UTC
